A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice

CompletedOBSERVATIONAL
Enrollment

145

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Oral Semaglutide

Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.

Trial Locations (1)

2408 AV

Master Centre Netherlands, Alphen aan den Rijn

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY